Follow The Filings

DAFNA Capital Management LLC Nathan Fischel

Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $524M
  • 88 holdings
  • 2026 Q2
  • +19.1% QoQ
  • Top 5 40.2%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 88 holdings

Top 5 40.2%, top 10 56.2%

  1. RVMD, Revolution Medicines 20.1%
  2. XBI, SPDR S&P Biotech ETF 5.9%
  3. CMPS, Compass Pathways 5.4%
  4. STXS, Stereotaxis 4.5%
  5. NKTR, Nektar Therapeutics 4.3%
  6. DNLI, Denali Therapeutics 3.6%
  7. IDYA, Ideaya Biosciences 3.5%
  8. ATRC, Atricure 3.2%
  9. XENE, Xenon Pharmaceuticals 2.9%
  10. CYTK, Cytokinetics 2.8%
  11. RCUS, Arcus Biosciences 2.6%
  12. ASND, Ascendis Pharma A/s 2.5%
  13. Other 38.7%

AUM over time

2026 Q2 $524M +19.1% QoQ
2021 Q3: $377M 2021 Q3: $377M
Q3 2021
2021 Q4: $398M, +5.6% QoQ 2021 Q4: $398M, +5.6% QoQ
Q4
2022 Q1: $384M, −3.5% QoQ 2022 Q1: $384M, −3.5% QoQ
Q1 2022
2022 Q2: $367M, −4.4% QoQ 2022 Q2: $367M, −4.4% QoQ
Q2
2022 Q3: $372M, +1.4% QoQ 2022 Q3: $372M, +1.4% QoQ
Q3
2022 Q4: $355M, −4.6% QoQ 2022 Q4: $355M, −4.6% QoQ
Q4
2023 Q1: $334M, −5.9% QoQ 2023 Q1: $334M, −5.9% QoQ
Q1 2023
2023 Q2: $366M, +9.6% QoQ 2023 Q2: $366M, +9.6% QoQ
Q2
2023 Q3: $321M, −12.3% QoQ 2023 Q3: $321M, −12.3% QoQ
Q3
2023 Q4: $417M, +29.9% QoQ 2023 Q4: $417M, +29.9% QoQ
Q4
2024 Q1: $439M, +5.3% QoQ 2024 Q1: $439M, +5.3% QoQ
Q1 2024
2024 Q2: $419M, −4.6% QoQ 2024 Q2: $419M, −4.6% QoQ
Q2
2024 Q3: $423M, +1.0% QoQ 2024 Q3: $423M, +1.0% QoQ
Q3
2024 Q4: $393M, −7.1% QoQ 2024 Q4: $393M, −7.1% QoQ
Q4
2025 Q1: $353M, −10.2% QoQ 2025 Q1: $353M, −10.2% QoQ
Q1 2025
2025 Q2: $362M, +2.5% QoQ 2025 Q2: $362M, +2.5% QoQ
Q2
2025 Q3: $405M, +11.9% QoQ 2025 Q3: $405M, +11.9% QoQ
Q3
2025 Q4: $431M, +6.4% QoQ 2025 Q4: $431M, +6.4% QoQ
Q4
2026 Q1: $440M, +2.1% QoQ 2026 Q1: $440M, +2.1% QoQ
Q1 2026
2026 Q2: $524M, +19.1% QoQ 2026 Q2: $524M, +19.1% QoQ
Q2

Book

2025 Q4 2025 Q3, filed 17 Feb, long equity only

Download CSV Download Excel All activity
RVMD, Revolution Medicines 11.18% Reduce −8.0% 604,514 $79.65 $48M −52,662 +$17M
XBI, SPDR S&P Biotech ETF 9.53%, was 9.94% Reduce −16.2% 336,505 $121.93 $41M −65,000 +$799K
STXS, Stereotaxis 7.31% Hold 13,680,554 $2.30 $31M — —
ATRC, Atricure 5.49%, was 5.16% Add +0.9% 597,431 $39.56 $24M +5,158 +$2.8M
CYTK, Cytokinetics 5.48% Reduce −6.1% 370,997 $63.54 $24M −23,943 +$1.9M
IDYA, Ideaya Biosciences 4.07% Reduce −6.1% 506,740 $34.57 $18M −33,183 +$2.8M
AXGN, Axogen 3.63% Reduce −35.8% 476,826 $32.73 $16M −265,456 +$2.4M
XENE, Xenon Pharmaceuticals 3.00% Hold 287,939 $44.82 $13M — —
NDAQ, iShares Nasdaq Biotech Indx 2.67%, was 3.66% Reduce −33.6% 68,095 $168.77 $11M −34,405 −$3.3M
BHVN, Biohaven 2.51%, was 0.87% Add +306.1% 955,235 $11.29 $11M +720,000 +$7.3M
RCUS, Arcus Biosciences 2.39% Reduce −31.3% 431,329 $23.83 $10M −196,297 +$1.7M
NBIX, Neurocrine Biosciences 2.33% Hold 70,615 $141.83 $10M — —
DAWN 2.16% Hold 999,163 $9.32 $9.3M — —
TNDM, Tandem Diabetes Care 1.81% Hold 355,208 $21.98 $7.8M — —
ASND, Ascendis Pharma A/s 1.40%, was 1.63% Reduce −15.1% 28,177 $213.24 $6M −5,000 −$587K
DXCM, DexCom 1.36%, was 1.09% Add +34.7% 88,279 $66.37 $5.9M +22,727 +$1.4M
SNDX, Syndax Pharmaceuticals 1.36%, was 1.90% Reduce −44.5% 277,855 $21.01 $5.8M −222,847 −$1.9M
Kalvista Pharmaceuticals 1.34% Reduce −15.6% 356,802 $16.15 $5.8M −65,929 +$613K
CMPS, Compass Pathways 1.30% Hold 811,046 $6.90 $5.6M — —
INGN, Inogen 1.29%, was 1.22% Add +36.6% 827,071 $6.72 $5.6M +221,446 +$610K
DNLI, Denali Therapeutics 1.22%, was 0.60% Add +89.0% 318,500 $16.51 $5.3M +150,000 +$2.8M
MBX, MBX Biosciences 1.21%, was 0.37% Add +94.4% 165,265 $31.54 $5.2M +80,265 +$3.7M
BCAX, Bicara Therapeutics 1.02%, was 1.24% Reduce −17.5% 261,583 $16.83 $4.4M −55,418 −$603K
LKFT, Galapagos 0.99% Hold 130,175 $32.70 $4.3M — —
ATXS, Astria Therapeutics 0.93% Reduce −4.7% 304,775 $13.09 $4M −15,000 +$1.7M
EWTX, Edgewise Therapeutics 0.92% Reduce −25.3% 159,736 $24.82 $4M −54,000 +$497K
IMVT, Immunovant 0.89% Reduce −21.4% 150,524 $25.42 $3.8M −40,969 +$739K
PRCT, Procept Biorobotics 0.88% New 120,000 $31.46 $3.8M +120,000 +$3.8M
CYBN, Cybin 0.86% New 455,018 $8.18 $3.7M +455,018 +$3.7M
ALKS, Alkermes 0.85%, was 1.00% Reduce −3.3% 130,248 $27.98 $3.6M −4,500 −$398K
LRMR, Larimar Therapeutics 0.83% Reduce −8.6% 939,164 $3.81 $3.6M −88,600 +$259K
STOK, Stoke Therapeutics 0.80%, was 0.99% Reduce −35.9% 108,875 $31.74 $3.5M −60,916 −$534K
LXEO, Lexeo Therapeutics 0.79% Reduce −4.8% 340,859 $9.93 $3.4M −17,224 +$1M
BCRX, Biocryst Pharmaceuticals 0.76%, was 0.41% Add +91.6% 418,255 $7.80 $3.3M +200,000 +$1.6M
NKTR, Nektar Therapeutics 0.74% Add +36.4% 74,998 $42.28 $3.2M +20,000 +$42K
PRQR, Proqr Therapeutics 0.74% Hold 1,567,561 $2.02 $3.2M — —
IPSC, Century Therapeutics 0.65%, was 0.21% Add +63.9% 2,793,586 $0.9948 $2.8M +1,089,354 +$1.9M
Immatics 0.64%, was 0.49% Add +11.1% 261,138 $10.50 $2.7M +26,138 +$740K
GPCR, Structure Therapeutics 0.60% Reduce −37.3% 37,000 $69.55 $2.6M −22,000 +$921K
MPLT, Maplight Therapeutics 0.59% New 143,764 $17.57 $2.5M +143,764 +$2.5M
ALGN, Align Technology 0.58%, was 0.34% Add +45.5% 16,000 $156.15 $2.5M +5,000 +$1.1M
KURA, Kura Oncology 0.57%, was 1.01% Reduce −49.1% 235,868 $10.39 $2.5M −227,500 −$1.7M
AQST, Aquestive Therapeutics 0.56%, was 0.71% Reduce −26.7% 375,915 $6.46 $2.4M −136,674 −$437K
RAPP, Rapport Therapeutics 0.53% Hold 75,000 $30.34 $2.3M — —
PROF, Profound Medical 0.52% New 285,710 $7.87 $2.2M +285,710 +$2.2M
SPRY, Ars Pharmaceuticals 0.51%, was 0.35% Add +35.3% 190,065 $11.65 $2.2M +49,565 +$802K
Mediwound 0.49% Hold 113,612 $18.46 $2.1M — —
VKTX, Viking Therapeutics 0.49% Reduce −7.8% 59,516 $35.18 $2.1M −5,000 +$398K
PODD, Insulet 0.45% Hold 6,870 $284.24 $2M — —
ALLO, Allogene Therapeutics 0.44% Hold 1,380,118 $1.37 $1.9M — —

Showing top 50 of 76 by value

Exits / last held

Gone since 2025 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
Merus BV 5.13% Exit 0 $94.15 $21M −220,451 −$21M
SLNO, Soleno Therapeutics 0.89% Exit 0 $67.60 $3.6M −53,000 −$3.6M
CMPX, Compass Therapeutics 0.82% Exit 0 $3.50 $3.3M −946,661 −$3.3M
Korro Bio 0.72% Exit 0 $47.89 $2.9M −60,804 −$2.9M
Keros Therapeutics 0.32% Exit 0 $15.82 $1.3M −80,716 −$1.3M
BDTX 0.29% Exit 0 $3.79 $1.2M −307,070 −$1.2M
URGN, Urogen 0.14% Exit 0 $19.95 $549K −27,515 −$549K
Sutro Biopharma 0.09% Exit 0 $0.8694 $380K −437,079 −$380K
Biomx 0.05% Exit 0 $0.5260 $211K −401,136 −$211K
APRE, Aprea Therapeutics 0.05% Exit 0 $1.47 $202K −137,174 −$202K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 88 $524M +19.1% 13F-HR 8/14/2026 000138993326000006
2026 Q1 83 $440M +2.1% 13F-HR 5/15/2026 000138993326000004
2025 Q4 77 $431M +6.4% 13F-HR 2/17/2026 000138993326000002
2025 Q3 75 $405M +11.9% 13F-HR 11/14/2025 000138993325000008
2025 Q2 76 $362M +2.5% 13F-HR 8/14/2025 000138993225000011
2025 Q1 83 $353M −10.2% 13F-HR 5/15/2025 000138993325000002
2024 Q4 82 $393M −7.1% 13F-HR 2/14/2025 000138993225000004
2024 Q3 84 $423M +1.0% 13F-HR 11/14/2024 000138993224000020
2024 Q2 83 $419M −4.6% 13F-HR 8/14/2024 000138993224000016
2024 Q1 72 $439M +5.3% 13F-HR 5/15/2024 000138993224000012
2023 Q4 76 $417M +29.9% 13F-HR 2/14/2024 000138993224000004
2023 Q3 75 $321M −12.3% 13F-HR 11/14/2023 000138993223000010
2023 Q2 73 $366M +9.6% 13F-HR 8/14/2023 000138993323000008
2023 Q1 72 $334M −5.9% 13F-HR 5/15/2023 000138993323000006
2022 Q4 79 $355M −4.6% 13F-HR 2/14/2023 000138993323000002
2022 Q3 87 $372M +1.4% 13F-HR 11/14/2022 000138993322000010
2022 Q2 90 $367M −4.4% 13F-HR 8/15/2022 000138993322000008
2022 Q1 94 $384M −3.5% 13F-HR 5/16/2022 000138993322000006
2021 Q4 87 $398M +5.6% 13F-HR 2/14/2022 000138993322000002
2021 Q3 80 $377M — 13F-HR 11/15/2021 000138993321000011

About

DAFNA Capital Management LLC

20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
DAFNA Capital Management LLC
Notable person
Nathan Fischel
Location
Los Angeles, CA
All SEC filings
View on sec.gov